A Phase 1 Study of ASP5834 in Participants with Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies with KRAS Mutations or KRAS Amplifications Read more
A phase 1 study of JNJ-86974680, an A2a receptor antagonist, administered as monotherapy and in combination with cetrelimab and radiotherapy for advanced nonsmall cell lung cancer Read more
A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Squamous Solid Tumors Read more
A Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors Read more
Real World Outcomes with Amivantamab Monotherapy in Patients with non-Exon 20 Insertion Epidermal Growth Factor Receptor (EGFR)-mutated Non-small Cell Lung Cancer (NSCLC) Read more
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients with Selected Advanced Solid Tumors Read more
An Investigational Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors Read more
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors Read more
Phase Ia, first in human open label, dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours Read more
